Only one of our models could value this stock with confidence, so use it as a guide.
Not used by alerts or posts.
Valued as a mature, profitable company: Discounted cash flow, P/E comparison, and Dividend discount.
ACCE opinionDENTSPLY SIRONA Inc. Common Stock (XRAY)
Fair value (2 models)
Not available
ACCE price target
$9.00
Rating
Not rated
Horizon
12 months
ACCE price target published on 11 Oct 2026, 00:00 CEST.
Price used: $9.43 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, Dividend discount, and P/E comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
38
out of 100
Analysts
24% buy
17 covering
1-year return
-28.3%
Dividend yield
0.00%
DENTSPLY SIRONA Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
DENTSPLY SIRONA makes dental consumables, equipment and digital imaging systems, including implants, endodontic files, restorative materials and CAD/CAM and intraoral scanning hardware sold through a large dentist installed base. The durable part of the franchise is the consumables mix, which carries a 49.5% gross margin and recurs with each procedure, so the question is how much of that base holds up through the current slowdown. Revenue is shrinking at 4.1% and ROE is -33%, which points to write-downs and a balance sheet that has absorbed losses rather than a business that is earning its way out. A forward P/E of 6.3 prices in a lot of that pessimism, but the 9.2% operating margin is thin for a company carrying this much restructuring baggage, and the score of 38/100 and absence from any index suggest the market is not yet paying for a turnaround. This deserves a deeper look mainly to test whether consumables volumes have bottomed and whether restructuring savings reach the operating line.
⚠ Investor warnings · 4 flagsAI-assisted·How I use AI
high
Heavy leverage, thin equity
Debt/Equity of 1.84 and ROE of -33.0% leave little cushion. Net margin of -15.0% against $104M FCF means earnings are not yet covering the debt load comfortably.
high
Revenue shrinking year on year
Revenue fell 4.1% year on year while the 5-year revenue CAGR is only 2.0%. Top-line momentum has turned negative.
moderate
Elevated short interest
Short interest sits at 14.3% of float, signalling meaningful bearish positioning among sophisticated investors.
moderate
Score down sharply in 90 days
The ACCE score fell from 49 to 38 over 90 days, with the margin component at just 17 and quality at 38.
AI research notes
AI-assisted·How I use AIWritten Oct 21, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
Free cash flow over the last 12 months was $104M, and the free cash flow yield is 6.2%.
Analysts' mean price target is $12.67, 42.8% above the share price, and the latest earnings beat expectations by 44.4%.
Why it could disappoint
Revenue fell 4.1% year over year, and the five-year average growth is only 2.0% a year, so the core business is shrinking.
Net margin is -15.0% and return on equity is -33.0%, so reported earnings are unreliable and the business is not earning its capital.
Debt to equity is 1.84, which leaves little room to absorb further shocks, and only 24% of analysts rate the stock Buy or Strong Buy.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 5, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where XRAY's valuation models land
Price
$9.43
Model fair valueConfidence: medium
$7.41
Model
Fair value
Upside
Discounted cash flow
Dividend discount
P/E comparison
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores